Speaker: 

Varun R Pulakanti, MD, Staff Member, Geisinger - has nothing to disclose.

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Intravenous Thrombolysis in Patients with Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants
• IV thrombolytics and DOACs: Do we need to look at our guidelines?
• A) Review what current guidelines tell us regarding use of DOACs and administration of IV thrombolytics for acute stroke. B) Discuss whether there is sufficient evidence to suggest that recent DOAC use is a relative, rather than absolute contraindication for IV thrombolytics.
• A) Do we need to come up with an objective means of deciding on whether it is safe to administer IV thromoblytics after recent DOAC use? B) Why do DOACs seem to be associated with lower bleeding complications despite still acting on the coagulation cascade? C) What role can DOAC reversal agents play in these clinical scenarios?
• Intravenous Thrombolysis in Patients with Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants
• IV thrombolytics and DOACs: Do we need to look at our guidelines?
• A) Review what current guidelines tell us regarding use of DOACs and administration of IV thrombolytics for acute stroke. B) Discuss whether there is sufficient evidence to suggest that recent DOAC use is a relative, rather than absolute contraindication for IV thrombolytics.
• A) Do we need to come up with an objective means of deciding on whether it is safe to administer IV thromoblytics after recent DOAC use? B) Why do DOACs seem to be associated with lower bleeding complications despite still acting on the coagulation cascade? C) What role can DOAC reversal agents play in these clinical scenarios?

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Anthony Noto, MD; Laura Fierke, PA-C and Lisa Wasko, BSN RN SCRN have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPPA compliant.